Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD).

Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD

SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells.

Bionano Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy Development

Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)

Bionano Genomics, Inc. (NASDAQ:BNGO ) Stifel Healthcare Conference Call November 15, 2023 1:50 PM ET Company Participants Erik Holmlin - CEO Conference Call Participants Dan Arias - Stifel Dan Arias Okay. Welcome back to the 2023 Stifel Healthcare Conference Day Two.

Bionano Genomics, Inc. (BNGO) Presents at Stifel Healthcare Conference (Transcript)

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the Association for Molecular Pathology (AMP) 2023 Annual Meeting and Expo with a broad range of content covering the utility of optical genome mapping (OGM) for cell and gene therapy and cancer research, including scientific workshops and poster presentations from Bionano and researchers from across the genomics landscape.

Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting

First Solar

Quanta Services

In general, stocks generate outsized returns because the Street has been overly bearish on their outlook. Due to the Street's overdone high interest rate concerns, it's now unduly pessimistic about many growth equities with great futures.

3 Stocks That Are Poised to Generate Outsized Returns

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Gülsen Kama - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Sung Ji Nam - Scotiabank Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call. Today's conference is being recorded.

Bionano Genomics, Inc. (BNGO) Q3 2023 Earnings Call Transcript

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023.

Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.

Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023

GlaxoSmithKline

One of the New York Yankees' most well-known players', Yogi Berra, famous for his strange, yet funny statements, used to say, “This is deja vu all over again.” That's how I feel about U.S. stocks at this point.

3 Deeply Undervalued Growth Stocks

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain business updates and unaudited preliminary financial results for the third quarter ended September 30, 2023.

Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA).

Benchmarking Study Shows Streamlined Structural Variant Detection and High Concordance for OGM Compared to Chromosomal Microarray Analysis, the Global Standard in Genetic Disease Analysis

Nano-X Imaging

Novavax

Biotech companies can offer some of the most explosive returns for an investor. Small-cap biotech companies are known to shoot up 100% overnight and also to dump 50% in an instant as well.

Ticking Time Bombs: 3 Biotech Stocks to Dump Before the Damage Is Done

SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that on September 18, 2023, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted an inducement award consisting of a non-qualified stock option to purchase 106,000 shares of common stock to Gülsen Kama, the Company's new Chief Financial Officer, under the Company's 2020 Inducement Plan, as amended. The Compensation Committee approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Bionano Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should Know

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese OEM partner, Ecobono, a distribution company focused on reproductive health products, has obtained reagent Class I registration from China's NMPA for Bionano's DNA isolation products. Ecobono is Bionano's third Chinese OEM partner to obtain approval from NMPA for Bionano's OGM solutions.

Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGM

SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families. The study authors conducted a comprehensive analysis of samples from the cohort in which non-sequencing-based challenges were encountered, and then reanalyzed samples using exome sequencing (ES), whole-genome sequencing (WGS), chromosomal microarray (CMA) and optical genome mapping (OGM), finding that addressing these challenges alone could boost diagnostic yield of causal variants by approximately 71% and underscoring the need for a thorough approach to undiagnosed diseases.

Largest Study of Mendelian Disease Highlights how OGM, alongside other Techniques, May Enhance Success Rates in Identifying Molecular Causes of Genetic Disease

EVgo

Rivian Automotive

Due to a combination of worries about high-interest rates, China's decision to prevent some government employees from using Apple's (NASDAQ: AAPL ) iPhones at work, and the fact that September is historically a very bad month for equities. many high-risk, high-reward stocks have taken a beating recently.

The 3 Best High-Risk, High-Reward Stocks to Buy Now: September 2023

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from researchers at the German Cancer Consortium (DKTK) showing the utility of optical genome mapping (OGM) and whole-exome sequencing (WES) in better understanding the mutational landscape of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Researchers compared the analysis of 60 pediatric BCP-ALL samples using traditional cytogenetic methods against OGM and WES, finding that OGM and WES may provide novel insights into disease development and progression.

Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and WES for Evaluation of Pediatric Leukemia

Hanesbrands

Mullen Automotive

Plug Power

WeWork

Wish

Workhorse Group

Sometimes I really question why we're still talking about meme stocks. When will investors learn that the unpredictable nature of meme stocks nearly always makes them a bad investment choice?

7 F-Rated Meme Stocks to Avoid Like the Plague

BlackBerry

Meme stocks feel like a relic of a bygone era. Indeed, all of the meme stocks that I can think of have been totally crushed since their heyday.

These Are the ONLY 3 Meme Stocks to Consider in August 2023

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has received a letter from the staff of the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”). As previously announced, the Company was notified by Nasdaq on May 30, 2023 that it was not in compliance with the Minimum Bid Price Requirement.   The notification letter noted that for the last 10 consecutive business days, from August 7, 2023 to August 18, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater, and thus the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.

Bionano Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab. CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for laboratory operations of quality, accuracy, and consistency, as outlined by CAP.

Bionano Laboratories Receives College of American Pathologists (CAP) Accreditation for its Clinical Laboratory

One of its top executives is departing. He will be replaced effective Sept.

News for Bionano Genomics Stock (BNGO)